26 results
Thumbnail

D2.426 - Polarization of PBMCs during SARS-CoV-2 Infections

Thumbnail

D2.432 - Therapeutic Efficacy of Platelet-Rich Plasma in Androgenic Alopecia: A Meta-Analysis of Single Versus Double-Blinded Randomized Controlled Trials

Thumbnail

D2.423 - Changes in the expression of regulatory receptors on CD8+ T cytotoxic lymphocytes as a marker of the risk of developing a post COVID-19 condition in patients after a severe course of COVID-19

Thumbnail

D2.425 - Type 2 neuro-immune signaling is upregulated in Candida albicans-driven itch

Thumbnail

D2.427 - Inhibition of the IL-17 pathway in the treatment of systemic vasculitis: molecular biology and case review

Thumbnail

D2.428 - Contribution of Allelic Gene Variants of the Indoleamine-2,3-Dioxygenase and Dectin-1 to the Risk of Invasive Aspergillosis in Oncohematological Patients

Thumbnail

D2.429 - Virus-Specific Regulatory T-Cell Dysregulation in Post-COVID-19 and EBV-Associated Vasculitis

Thumbnail

D2.430 - Automated 24-Hour Quantification of Scratching Behavior Reveals Distinct Physiological and Allergic Pruritus Signatures in Mice

Thumbnail

D2.433 - Clinical and Oxidative Function Profiles in Heterozygous Female Carriers of X-Linked Chronic Granulomatous Disease

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis